362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical &amp; translational analysis

James Spicer; Åslaug Helland; Enric Carcereny; Edurne Arriola; Manuel Dómine Gomez; Jose Manuel Trigo Perez; Jonathan Thompson; James Strauss; Ana Laura Ortega Granados; Enriqueta Felip; Emmett Schmidt; Michael Chisamore; Noelly Madeleine; Austin Rayford; Katherine Lorens; Abdul Siddiqui; Hani Gabra; Jaya Nautiyal; David Micklem; James Lorens; Matthew Krebs

doi:10.1136/jitc-2020-SITC2020.0362

Citation Tools

Regular and young investigator award abstracts

Clinical trials in progress

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Spicer J, Helland Å, Carcereny E, et al

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0362

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password